人 MECOM 抗体对
01AB02503
MDS1 and EVI1 complex locus (MECOM) encodes transcriptional regulators that function as both repressors and coactivators to modulate genes involved in hematopoiesis, development, and stem cell differentiation. MECOM proteins localize to the nucleus, where they bind specific DNA motifs via C2H2 zinc fingers and recruit histone-modifying cofactors such as CBP/p300 and histone methyltransferases. These interactions shape chromatin architecture and regulate signaling pathways, including TGF-β/SMAD, Notch, and VEGF. MECOM is essential for the maintenance of hematopoietic stem cells and endothelial lineage specification. Pathologically, MECOM acts as a proto-oncogene; its overexpression or genomic rearrangement is a hallmark of aggressive myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), where it is associated with poor clinical prognosis.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- MECOM
- 基因别名
- EVI1; MDS1; PRDM3
- 蛋白别名
- MDS1 and EVI1 complex locus; MECOM
- UniProt
- Q03112
- 物种
- Human
产品详情
- 靶点名称
- MECOM
- 蛋白名称
- MDS1 and EVI1 complex locus
- 蛋白别名
- Histone-lysine N-methyltransferase MECOM; Ecotropic virus integration site 1 protein homolog; EVI-1; MDS1 and EVI1 complex locus protein; Myelodysplasia syndrome 1 protein; Myelodysplasia syndrome-associated protein 1
- 靶点基因名
- MECOM
- 基因别名
- EVI1; MDS1; PRDM3
- UniProt
- Q03112
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
MDS1 and EVI1 complex locus (MECOM) encodes transcriptional regulators that function as both repressors and coactivators to modulate genes involved in hematopoiesis, development, and stem cell differentiation. MECOM proteins localize to the nucleus, where they bind specific DNA motifs via C2H2 zinc fingers and recruit histone-modifying cofactors such as CBP/p300 and histone methyltransferases. These interactions shape chromatin architecture and regulate signaling pathways, including TGF-β/SMAD, Notch, and VEGF. MECOM is essential for the maintenance of hematopoietic stem cells and endothelial lineage specification. Pathologically, MECOM acts as a proto-oncogene; its overexpression or genomic rearrangement is a hallmark of aggressive myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), where it is associated with poor clinical prognosis.